164 pages  

Date published
March 2007  

Additional info
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.  

Kerri Kelley
Customer Service

Delivery Technologies for Protein Therapeutics Tables and Figures

Delivery Technologies for Protein Therapeutics: Assessment and Outlook 

Tom Hollon, Ph.D


Table 1.1. Companies Targeting Improved Insulin Delivery
Table 1.2. Companies Targeting Improved Erythropoietin Delivery
Table 1.3. Companies Targeting Improved Growth Hormone Delivery
Table 1.4. Companies Targeting Improved Interferon Delivery
Table 1.5. Companies Targeting Improved Parathyroid Hormone Delivery
Table 2.1. Technologies for Extending Therapeutic Protein Half-life
Table 2.2. FDA-Approved Therapeutic Proteins Engineered for Extended Half-life


Figure 2.1. Multiple Benefits of Extending Half-life
Figure 2.2. PEG Mechanisms for Drug Delivery
Figure 2.3. SWOT Analysis for Releasable Pegylation
Figure 2.4. ReCODE: Biosynthetic Incorporation of Chemically Specified Amino Acids
Figure 2.5. SWOT Analysis for Site-specific Pegylation
Figure 2.6. Polysialic Acid Protects Against Proteases
Figure 2.7. Extending Therapeutic Protein Half-Life with Human Serum Albumin Fusion Technology
Figure 2.8. SWOT Analysis for Albumin Gene Fusion
Figure 2.9. SWOT Analysis for Albumin Conjugation
Figure 2.10. Structure of Insulin Detemir
Figure 2.11. SWOT Analysis for Albumin-binding peptides
Figure 2.12. Tertiary Structure of an Affibody Molecule
Figure 2.13. Peptide Fused via a Peptide Linker to the N Terminus of Transferrin
Figure 2.14. SWOT Analysis for Hyperglycosylation
Figure 2.15. Glycolylation Pattern Depends on Expression System
Figure 2.16. Enzymes Add Missing Sugars
Figure 2.17. PEGylation of a Protein on a Carbohydrate Chain
Figure 2.18. SWOT Analysis for Glycopegylation
Figure 2.19. SWOT Analysis for Humanized Glycosylation in Yeast
Figure 2.20. SWOT Analysis for Pretease-Resistant Point Mutations
Figure 3.1. Typical Effects of PreEMT System Pressure on Protein Aggregates
Figure 4.1. Micro Processor
Figure 4.2. Delivery of Insulin in Humans
Figure 4.3. SWOT Analysis for Transdermal Delivery of Proteins via RF-Microchannels
Figure 4.4. SWOT Analysis for Active Delivery by Ultrasound
Figure 4.5. SWOT Analysis for Passive Delivery by Ultrasound
Figure 4.6. Transdermal Delivery by Charge Repulsion
Figure 4.7. Dosage Patterns for Actyve
Figure 4.8. SWOT Analysis for Delivery by Iontophoresis
Figure 4.9. SWOT Anslysis for Delivery by Transferomes
Figure 5.1. Oral Delivery by Carrier Molecules
Figure 5.2. SWOT Analysis for Oral Protein Delivery Using Carrier Molecules
Figure 5.3a. Toxic Metabolites in the Blood Before Therapy
Figure 5.3b. Metabolite Gradient Set in Motion by Protein Crystals
Figure 5.4. SWOT Analysis for Oral Protein Delivery by Protein Crystalization
Figure 5.5. Calcium-PEG-Insulin-Casein
Figure 5.6. SWOT Analysis for RapidMist Buccal Protein Delivery
Figure 5.7. SWOT Analysis for Protein Delivery with Amphiphilic Oligomers
Figure 6.1. SWOT Analysis of Pulmonary Protein Delivery Using Dry Powder Inhalers
Figure 6.2. Epithelial Pinocytosis of Fc Therapeutic Fusion Proteins
Figure 6.3. Structures of Syntonix Therapeutic Fusion Proteins
Figure 6.4. SWOT Analysis of Pulmonary Protein Delivery Using Antibody Transcytosis Fusion Proteins
Figure 6.5. SWOT Analysis of Intranasal Protein Delivery Using Aegis Therapeutics’ Mucosal Absorption Enhancers
Figure 6.6. SWOT Analysis of Intranasal Protein Delivery Using Bentley Pharmaceuticals’ Mucosal Absorption Enhancers
Figure 6.7. Junctions Between Epithelial Cells

Appendix Figures: CHI Insight Pharma Reports – Protein Drug Delivery Survey – December 2006

Figure 1A. Respondents by Sector
Figure 2A. Focus of Respondents
Figure 3A. Delivery Technologies and New Indications for Drugs
Figure 4A. Technologies and Competitiveness
Figure 5A. PEGylation Dominance in the Marketplace
Figure 6A. Trend in Increasing Half-Life of Therapeutic Proteins
Figure 7A. Competitors’ Use of Longer Half-Life Proteins
Figure 8A. Alternatives to Injection
Figure 9A. Competitors and Injection
Figure 10A. Noninjection and Patient Compliance
Figure 11A. Improved Technologies and Prices of Treatments
Figure 12A. Involvement with Approved Therapies
Figure 13A. Oral Protein Delivery vs. Transdermal
Figure 14A. …. vs. Pulmonary
Figure 15A. …. Nasal
Figure 16A. Specialist vs. Primary Care
Figure 17A. Longer Half-Lives vs. Injection
Figure 18A. Noninjection Monoclonal Antibodies